Skip to main content
Equibles
VNDA logo

VNDA · Vanda Pharmaceuticals Inc.

Track VNDA — free

Use VNDA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about VNDA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$5.38 -0.19 (-3.41%) At close · Aug 20
Market Cap
$325.29M
Shares
60.46M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.38 Open$5.52 Day$5.32–5.52 52W close$4.32–9.56 Avg vol 30d990K Short int7.4M · 12.3% float · 9.0d Short vol46% Last earningsAug 5, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −18%
      below
      Price vs 50-day avg −4%
      below
      RSI (14) 50
      neutral
      MACD trend Positive
      52-week position 20%
      mid-range
      Momentum
      relative strength
      Very Weak
      1-month return 0%
      trailing
      6-month return −40%
      trailing
      YTD return −39%
      this year
      Relative strength −51%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $6 › 200d $7 — 200d above 50d
      Institutional flow Flat
      0% holders QoQ · +28 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      12.28% of float · ▲ +3.3% MoM · 9.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      171 holders — mid 3-yr range
      Squeeze score 74
      high risk · 0–100
      Fundamentals
      Fair
      Revenue growth +9%
      Y/Y
      EPS growth −1033%
      Y/Y
      Free cash flow $-110.4M
      Balance sheet $84.9M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 82%
      annualized · 1-yr
      Max drawdown −48%
      past year
      ATR 4.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 5, 2026
      Total revenues · Full Year 2026 Initiated $240M – $290M
      prior FY $216.11M midpoint +22.6% Y/Y
      Fanapt® and BYSANTI™ net product sales · Full Year 2026 Initiated $150M – $170M
      Other net product sales · Full Year 2026 Initiated $80M – $90M
      NEREUS™ net product sales · Full Year 2026 Initiated $10M – $30M
      Prior guidance period ended · from the 8-K filed Oct 29, 2025
      Total revenues · Full Year 2025 $210M – $230M
      Year-end 2025 Cash · Year-end 2025 $260M – $290M
      Guided vs delivered · last 1 settled
      Total revenues Full Year 2025
      guided $210M – $230M
      $216.11M In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −18% Bearish
      Price vs 50-day avg
      −4% Neutral
      RSI (14)
      50 Neutral
      MACD trend
      Positive Bullish
      52-week position
      20% Neutral
      Market signals — smart money & positioning
      Bearish · 1 of 6
      Trend (MA cross) No cross
      50d $6 › 200d $7 — 200d above 50d
      Institutional flow Flat
      0% holders QoQ · +28 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      12.28% of float · ▲ +3.3% MoM · 9.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      171 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $4 Now $5 · 20% Range high $10
      vs 200-day avg -18% vs 50-day avg -4%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Fanapt® new-to-brand prescriptions (NBRx) 32% Q2 2026 —
      Fanapt® total prescriptions (TRx) 31% Q2 2026 —
      Fanapt® weekly TRx (week ending April 24, 2026) 2,600 week ending April 24, 2026 —
      Non-GAAP effective tax rate non-GAAP 23% Twelve Months Ended December 31, 2025 —
      Non-GAAP net loss per share, diluted non-GAAP -$1.81 Twelve Months Ended December 31, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      VNDA
      Vanda Pharmaceuticals Inc.
      this stock
      		$325.29M -39.0% +8.7% — 12.3%
      ONC
      BeOne Medicines Ltd.
      		 $557.05B +21.5% +22179.2% 856.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $136.93B +19.2% +46.2% 31.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $86.39B +7.1% +20.8% 20.8 3.3%
      MRNA
      Moderna, Inc.
      		 $69.62B +352.1% +4.3% — 12.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      171
      % held
      82.5%
      Net QoQ
      +3.1M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      192
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      7.4M
      Days to cover
      9.0d
      Change
      +234.7K sh
      View
      Short Volume
      Short vol %
      46%
      As of
      Aug 20, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      5.0K
      Value
      $29.0K
      As of
      Jul 16, 2026
      View
      Off-Exchange
      Off-exchange %
      42.4%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $216.1M
      Net income (FY)
      $-220.5M
      EPS diluted
      $-3.74
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Aug 6, 2026
      This year
      15
      View
      Proposed Sales
      Value
      $254.6K
      Shares
      30.8K
      Filed
      Mar 2, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      VNDA +7.0% +0.4% -39.6% +5.5% -39.0%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY +8.9% -2.9% -50.8% +3.4% -50.8%
      Key facts CIK 1347178 CUSIP 921659108 13F (30d) 159 filings 156 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)